Leaflet GLUADDA 50mg tablets

Product code:
W66805004
Quantity:
30
Indicated for:
type 2 diabetes mellitus
Route of administration:
oral
Substance:
vildagliptin (DPP-4 inhibitor)
ATC
A10BH02 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Dipeptidyl peptidase 4 (DDP-4) inhibitors
Vildagliptin is a medication used for the treatment of type 2 diabetes. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones help regulate blood sugar by stimulating insulin secretion and reducing glucagon production, depending on blood glucose levels.

Vildagliptin is taken orally, usually once or twice daily, and can be used alone or in combination with other antidiabetic medications, such as metformin. It is effective in lowering blood sugar levels without typically causing episodes of hypoglycemia.

Side effects may include dizziness, headache, nausea, or, in rare cases, allergic reactions. It is important to use vildagliptin as directed by a healthcare provider, and patients should regularly monitor their blood sugar levels and maintain a healthy lifestyle to maximize the benefits of the treatment.

General data about GLUADDA 50mg

Substance:
vildagliptin
Date of latest medicines list:
01-10-2025
Product code:
W66805004
Concentration:
50mg
Pharmaceutical form:
tablets
Quantity:
30
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
COMBINO PHARM (MALTA) LTD. - MALTA
Holder:
MERCK ROMANIA SRL - ROMANIA
Number:
13276/2020/04
Shelf life:
3 years

Concentrations available for vildagliptin

  • 100mg
  • 50mg

Combinations with other substances